Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients. VP-102, our lead product candidate, is a drug-device combination topical therapy that has the potential to be the first product approved by the FDA to treat molluscum contagiosum (molluscum). If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name, YCANTH™. Results suggest that YCANTH™, if approved, could potentially improve both clinical practice and patient outcomes by providing molluscum patients with a new treatment option. We are also studying VP-102 for other dermatologic diseases, including common warts and external genital warts, which are also contagious and have substantial social stigma.

The company has also entered a worldwide license agreement with Lytix Biopharma AS (“Lytix”) to develop and commercialize LTX-315 for dermatologic oncology conditions. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indication for development.